medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 1

<< Back Next >>

Ann Hepatol 2018; 17 (1)

Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection

Ahmed H, Abushouk AI, Menshawy A, Attia A, Mohamed A, Negida A, Abdel-Daim MM

Language: English
References: 51
Page: 18-32
PDF size: 277.28 Kb.


ABSTRACT

Background and aim. Grazoprevir is an NS3/4A protease inhibitor (PI), while elbasvir is an NS5A inhibitor. We performed this meta-analysis to directly compare grazoprevir plus elbasvir and ribavirin regimen vs. grazoprevir and elbasvir without ribavirin in the treatment of hepatitis C virus genotype 1 infection and to precisely evaluate the efficacy of the latter regimen in cirrhotic, IL28 CC genotype patients and those coinfected with human immunodeficiency virus. Material and methods. A computer literature search of PubMed, Scopus, EBSCO, Embase, and Cochrane central was conducted. Studies were screened for eligibility. Sustained virologic response (SVR) rates were pooled using OpenMeta [Analyst] software for windows. A subgroup analysis was performed to stratify the treatment efficacy according to the different baseline characteristics of HCV patients. Results. Eight randomized controlled trials (n = 1,297 patients) were pooled in the final analysis. The overall SVR rate was 96.6% with 95% CI [95.5% to 98%]. For cirrhotic patients, the SVR rate was 95.7% with 95% CI [93.9% to 97.5%] and for non-cirrhotic patients, the SVR rate was 97% with 95% CI [95.9% to 98.4%]. Furthermore, the addition of ribavirin (RBV) to the treatment regimen did not significantly improve the SVR (RR 1.003, 95% CI [0.944 to 1.065]).The dual regimen was effective in patient populations with NS3 resistance-associated substitution (RAS). However, this regimen achieved lower SVR rates (‹ 90%) in patients with NS5A RAS. Conclusions. We conclude that the 12-week treatment regimen of the fixed dose combination of grazoprevir plus elbasvir achieved high SVR rates in patients with HCV genotype 1 infection. The addition of ribavirin to this regimen did not add a significant benefit.


REFERENCES

  1. The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology & Hepatology 2017; 2: 161-76.

  2. European Association for the Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199-236.

  3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.

  4. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21, 521-6.

  5. Blonski W, Reddy KR. Hepatitis C virus infection and hepatocellular carcinoma. Clinics in liver disease 2008; 12: 661-74, x.

  6. Lee M-H, Yang H-I, Yuan Y, L’Italien G, Chen C-J. Epidemiology and natural history of hepatitis C virus infection. WJG 2014; 20: 9270-80.

  7. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.

  8. Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.

  9. Ward RP, Kugelmas M. Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C. American Family Physician 2005; 72: 655-62.

  10. Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrobial Agents and Chemotherapy 2014; 58: 4995.

  11. Yao Y, Yue M, Wang J, Chen H, Liu M, Zang F, et al. Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis. Can J Gastroenterol Hepatol 2017; 8186275.

  12. Lahser F, Liu R, Bystol K, Xia E, Raubertas R, Asante-Appiah E, Liu R, et al. A combination containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in vitro in HCV replicons. Hepatology 2012; 56: 236A.

  13. Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 2015; 63: 564-72.

  14. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous. The Lancet 2015; 385: 1075-86.

  15. Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir ( MK-5172 ) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV / hepatitis C virus co-infection ( C-WORTHY ). The Lancet 2014; 6736: 1-11.

  16. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, et al. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Non-cirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection A Randomized Trial. Ann Int Med 2015; 163: 1-13.

  17. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. The Lancet HIV 2015; 2: e319-e327.

  18. Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Jr HM, Martin P, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4 – 5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015; 6736: 1-9.

  19. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann Intern Med 2016; 165: 625-34.

  20. Sperl J, Horvath G, Halota W, Ruiz-Tapiador JA, Streinu-Cercel A, Jancoriene L, Werling K, et al. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: a phase III randomized controlled trial. J Hepatol 2016; 65: 1112-9.

  21. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 2009; 6: e1000097.

  22. Series CB, Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Wiley Online Library 2008.

  23. 23 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed) 1997; 315: 629-34.

  24. Harbord RM, Egger M, Sterne JA. A modified test for smallstudy effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006; 25: 3443-57.

  25. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New Engl J Med 1998; 339: 1485-92.

  26. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FLJ, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 2002; 347: 975-82.

  27. Sulkowski M, Reindollar R, Thomas DL, Brinkley-Laughton S, Hudson M, Yu J. Peginterferon-alpha-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open-label study. BioDrugs 2002; 16: 105-9.

  28. Camps J, García N, Riezu-Boj JI, Civeira MP, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993; 19: 408-12.

  29. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591-8.

  30. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Int Med 1995; 123: 897-903.

  31. Ahmed H, Elgebaly A, Abushouk AI, Hammad AM, Attia A, Negida A. Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis. Antiviral therapy 2016. Doi:10.3851/IMP3083.

  32. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle B, Martin R, Zeuzem S, Lawitz E. et al. P0773: The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/ sofosbuvir+/-RBV. J Hepatol 2015; 62: S620.

  33. Gambarin-Gelwan M, Jacobson IM. Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors. Current Gastroenterology Reports 2012; 14: 47-54.

  34. Feld JJ, Jacobson IM, Sulkowski MS, Poordad F, Tatsch F, Pawlotsky J. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liv Internat 2016.

  35. van der Ree MH, van der Meer AJ, de Bruijne J, Maan R, van Vliet A, Welzel TM, Zeuzem S, et al. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antiviral Research 2014; 111: 53-9.

  36. Reddy KR, Beavers KL, Gordon S, Harrison S, Reau N, Yozviak J, DeLedinghen V, et al. P0889: Effect of baseline factors on response to the fixed-dose combination of daclatasvir (DCV), asunaprevir (ASV) and beclabuvir (BCV) in non-cirrhotic patients with HCV genotype 1 infection. J Hepatol 2015; 62: S676-S677.

  37. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz l, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet 2014; 384: 403-13.

  38. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hézode C, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-41. e6.

  39. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Eng J Med 2014; 370: 1973-82.

  40. Therapeutics J. OLYSIO (simeprevir) prescribing information. Janssen Therapeutics, Titusville, NJ. Available from: http://www accessdata fda gov/drugsatfda_docs/label/ 2013/205123s001lbl pdf Accessed 2014; 15.

  41. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Mitchell L, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Eng J Med 2014; 370: 1879-88.

  42. Thompson A, Zeuzem S. The Combination of Elbasvir and Grazoprevir ± RBV Is Highly Effective for the Treatment of GT1a-Infected Patients. In: Presented at the American Association for the Study of Liver Diseases Liver Meeting. 2015. Available from: http://www.natap.org/2015/AASLD/ AASLD_18.htm.

  43. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313: 1223-31.

  44. Molina J-M, Orkin C, Iser DM, Zamora F-X, Nelson M, Stephan C, Massetto B, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON- 2): a multicentre, open-label, non-randomised, phase 3 study. The Lancet 2015; 385: 1098-106.

  45. Wyles D, Ruane P, Sulkowski M, Dieterich D, Luetkemeyer AF, Morgan TR. Daclatasvir in combination with sofosbuvir for HIV/HCV coinfection: ALLY-2 study. In: 22nd conference on retroviruses and opportunistic infections. 2015, pp. 23-6.

  46. Naggie S, Cooper C, Saag M, Yang JC, Stamm LM, Pang PS, McHutchison JG, et al. Ledipasvir/sofosbuvir for 12 weeks in patients co-infected with HCV and HIV-1. In: Journal of The International AIDS Society. Int AIDS Society Avenue De France 23, Geneva, 1202, Switzerland, 2015.

  47. Rodriguez-Torres M, Slim J, Bhatti L, Sterling R, Sulkowski M, Hassanein T, Slim J, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clinical Trials 2012; 13: 142-52.

  48. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Int Med 2004; 140: 346-55.

  49. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.

  50. Lawitz E, Poordad F, Gutierrez JA, Evans B, Hwang P, Robertson M, Stypinski C, et al. C-SWIFT: MK-5172+ MK-8742+ sofosbuvir in treatment-naive patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, for durations of 4, 6, or 8 weeks. In: Hepatology. Wiley-Blackwell 111 River St., Hoboken 07030-5774, NJ, USA; 2014, p. 1286A-1287A.

  51. Buti M, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, et al. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection after Failure of Pegylated Interferon and Ribavirin with an Earlier-Generation Protease Inhibitor: Final 24-Week Results from C-SALVAGE. Clin Infect Dis 2016; 62: 32-6.




2020     |     www.medigraphic.com